FTC Accuses Endo Pharmaceuticals Of "Pay-For-Delay" Agreements; Analysts Not Worried

01AprApril 1, 2016

FTC Accuses Endo Pharmaceuticals Of "Pay-For-Delay" Agreements; Analysts Not Worried

The Federal Trade Commission said Thursday that Endo Pharmaceuticals violated federal antitrust laws by paying Impax Laboratories and Watson Laboratories to delay launching their approved generic versions. The latest case is the first by the commission that challenges an agreement not to market an authorized generic.

FTC claims "pay-for-delay" agreements cost consumers billions

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.

Author

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Will China’s New “Supply-Side” Reforms Help China? – Pettis

Jan

Will China's New "Supply-Side" Reforms Help China? by Michael Pettis, China Financial Markets It wasn’t enough that we started 2016 with one of the worst weeks in the recent history... Read More

ETF Problems ETF growth assets under management 1998 to 2025 projected

Legg Mason Debuts ETFs

Jan

Legg Mason has launched four new outcome-oriented index-based exchange-traded funds in partnership with its investment affiliate QS Investors. The launch of the four ETFs marks the entry of the mutual... Read More

Sushi Roll Economics

Oct

During their recent episode of the VALUE: After Hours Podcast, Taylor, Brewster, and Carlisle discussed Sushi Roll Economics. Here’s an excerpt from the episode: Q3 2020 hedge fund letters, conferences... Read More

Jeff Auxier Asset Management – 'Hazelnuts, Cows… and Stocks'

Jan

Auxier Asset Management's letter to shareholders for the period ended 9/30/2014 titled 'Hazelnuts, Cows… and Stocks.' As of 9/30/14 the Stock Portion of the Investor Class, AUXFX, is Up 360%... Read More

[Archives] Is Management Quality Value Relevant?

Jun

Is Management Quality Value Relevant? via CSInvesting Vineet Agarwal Cranfield School of Management Richard Taffler The Management School, University of Edinburgh Mike Brown Nottingham Business School 15 January 2007 Abstract Using a unique database of management ratings over... Read More